Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Concurrent Ponatinib With Chemotherapy for Young Adults With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Next Previous
X
Search
Trial Profile

Concurrent Ponatinib With Chemotherapy for Young Adults With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ponatinib (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Daunorubicin; Etoposide; Hydrocortisone; Mercaptopurine; Methotrexate; Methotrexate; Prednisone; Prednisone; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PONALFIL

    • Most Recent Events

    • 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 10 Feb 2021 Planned End Date changed from 1 Jan 2023 to 1 Aug 2023.
    • 10 Feb 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top